A Case for the Use of Artificial Intelligence in Glaucoma Assessment

Collaborative Community on Ophthalmic Imaging Executive Committee and Glaucoma Workgroup

doi:10.1016/j.ogla.2021.12.003

A Case for the Use of Artificial Intelligence in Glaucoma Assessment

Collaborative Community on Ophthalmic Imaging Executive Committee and Glaucoma Workgroup

Medicine

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

We hypothesize that artificial intelligence (AI) applied to relevant clinical testing in glaucoma has the potential to enhance the ability to detect glaucoma. This premise was discussed at the recent Collaborative Community on Ophthalmic Imaging meeting, “The Future of Artificial Intelligence–Enabled Ophthalmic Image Interpretation: Accelerating Innovation and Implementation Pathways,” held virtually September 3–4, 2020. The Collaborative Community on Ophthalmic Imaging (CCOI) is an independent self-governing consortium of stakeholders with broad international representation from academic institutions, government agencies, and the private sector whose mission is to act as a forum for the purpose of helping speed innovation in healthcare technology. It was 1 of the first 2 such organizations officially designated by the Food and Drug Administration in September 2019 in response to their announcement of the collaborative community program as a strategic priority for 2018–2020. Further information on the CCOI can be found online at their website (https://www.cc-oi.org/about). Artificial intelligence for glaucoma diagnosis would have high utility globally, because access to care is limited in many parts of the world and half of all people with glaucoma are unaware of their illness. The application of AI technology to glaucoma diagnosis has the potential to broadly increase access to care worldwide, in essence flattening the Earth by providing expert-level evaluation to individuals even in the most remote regions of the planet.

Original language	English
Pages (from-to)	e3-e13
Journal	Ophthalmology. Glaucoma
Volume	5
Issue number	3
DOIs	https://doi.org/10.1016/j.ogla.2021.12.003
Publication status	Published - May 1 2022

Bibliographical note

Funding Information:
L.A.A.: Consultant/Advisor – Aerie Pharmaceuticals, Inc; Equity Owner – GlobeChek; Advisor – AI Optics, Zeiss; Grant Support – New World Medical Inc, Save Vision Foundation; Research support and consultant – Topcon Medical Systems Inc; Consultant – Verily.

Funding Information:
The author(s) have made the following disclosure(s): J.S.S.: Consultant/Advisor, Equity Owner – Aerie Pharmaceuticals Inc, Ocular Therapeutix Inc, Opticient; Grant Support – BrightFocus Foundation, National Eye Institute; Consultant/Advisor – Boehringer Ingelheim, Perfuse Inc, Regeneron Inc, Slack Incorporated; Patents/Royalty/Consultant/Advisor – Carl Zeiss Meditec; Intellectual Property – Massachusetts Eye and Ear Infirmary and Massachusetts Institute of Technology, New York University, Tufts University, University of Pittsburgh; Equity Owner, Patents/Royalty – Ocugenix.. L.A.A.: Consultant/Advisor – Aerie Pharmaceuticals, Inc; Equity Owner – GlobeChek; Advisor – AI Optics, Zeiss; Grant Support – New World Medical Inc, Save Vision Foundation; Research support and consultant – Topcon Medical Systems Inc; Consultant – Verily.. M.C.: Grant support – NIH, NSF, Genentech; Consultant – Novartis; Equity owner – InTeleretina, LLC.. F.A.M.: Consultant – Aerie Pharmaceuticals, Annexon, Biogen, Galimedix, IDx, Stealth Biotherapeutics; Consultant/Financial support – Allergan, Carl ZeissMeditec, Reichert, Novartis; Financial support – Google Inc, Heidelberg Engineering, Novartis; Patent – nGoggle Inc.. L.Z.: Grant support – National Eye Institute; Equipment and research support – Carl Zeiss Meditec Inc, Heidelberg Engineering GmbH, Optovue Inc, Topcon Medical Systems Inc, Patent Zeiss Meditec.. Financial Support: Funding from the National Institutes of Health (Bethesda, MD) R01-EY013178 and an unrestricted grant from Research to Prevent Blindness (New York, NY) to the Department of Ophthalmology, NYU Langone Health, NYU Grossman School of Medicine (New York, NY).. Obtained funding: N/A; Study was performed as part of the authors' regular employment duties. No additional funding was provided.

Funding Information:
M.C.: Grant support – NIH, NSF, Genentech; Consultant – Novartis; Equity owner – InTeleretina, LLC.

Publisher Copyright:
© 2022 American Academy of Ophthalmology

ASJC Scopus Subject Areas

Ophthalmology
General Medicine

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

Access to Document

10.1016/j.ogla.2021.12.003

Cite this

@article{81a4b9291c71431f834c8f2eef118480,

title = "A Case for the Use of Artificial Intelligence in Glaucoma Assessment",

abstract = "We hypothesize that artificial intelligence (AI) applied to relevant clinical testing in glaucoma has the potential to enhance the ability to detect glaucoma. This premise was discussed at the recent Collaborative Community on Ophthalmic Imaging meeting, “The Future of Artificial Intelligence–Enabled Ophthalmic Image Interpretation: Accelerating Innovation and Implementation Pathways,” held virtually September 3–4, 2020. The Collaborative Community on Ophthalmic Imaging (CCOI) is an independent self-governing consortium of stakeholders with broad international representation from academic institutions, government agencies, and the private sector whose mission is to act as a forum for the purpose of helping speed innovation in healthcare technology. It was 1 of the first 2 such organizations officially designated by the Food and Drug Administration in September 2019 in response to their announcement of the collaborative community program as a strategic priority for 2018–2020. Further information on the CCOI can be found online at their website (https://www.cc-oi.org/about). Artificial intelligence for glaucoma diagnosis would have high utility globally, because access to care is limited in many parts of the world and half of all people with glaucoma are unaware of their illness. The application of AI technology to glaucoma diagnosis has the potential to broadly increase access to care worldwide, in essence flattening the Earth by providing expert-level evaluation to individuals even in the most remote regions of the planet.",

author = "{Collaborative Community on Ophthalmic Imaging Executive Committee and Glaucoma Workgroup} and Schuman, {Joel S.} and {De Los Angeles Ramos Cadena}, Maria and Rebecca McGee and Al-Aswad, {Lama A.} and Medeiros, {Felipe A.} and Michael Abramoff and Mark Blumenkranz and Emily Chew and Michael Chiang and Malvina Eydelman and David Myung and Carol Shields and Antony, {Bhavna J.} and Tin Aung and Michael Boland and Tom Brunner and Chang, {Robert T.} and Balwantray Chauhan and Cherwek, {D. Hunter} and David Garway-Heath and Adrienne Graves and Goldberg, {Jeffrey L.} and Minguang He and Naama Hammel and Donald Hood and Hiroshi Ishikawa and Chris Leung and Louis Pasquale and Quigley, {Harry A.} and Roberts, {Calvin W.} and Robin, {Alan L.} and Elena Sturman and Remo Susanna and Jayme Vianna and Linda Zangwill",

note = "Funding Information: L.A.A.: Consultant/Advisor – Aerie Pharmaceuticals, Inc; Equity Owner – GlobeChek; Advisor – AI Optics, Zeiss; Grant Support – New World Medical Inc, Save Vision Foundation; Research support and consultant – Topcon Medical Systems Inc; Consultant – Verily. Funding Information: The author(s) have made the following disclosure(s): J.S.S.: Consultant/Advisor, Equity Owner – Aerie Pharmaceuticals Inc, Ocular Therapeutix Inc, Opticient; Grant Support – BrightFocus Foundation, National Eye Institute; Consultant/Advisor – Boehringer Ingelheim, Perfuse Inc, Regeneron Inc, Slack Incorporated; Patents/Royalty/Consultant/Advisor – Carl Zeiss Meditec; Intellectual Property – Massachusetts Eye and Ear Infirmary and Massachusetts Institute of Technology, New York University, Tufts University, University of Pittsburgh; Equity Owner, Patents/Royalty – Ocugenix.. L.A.A.: Consultant/Advisor – Aerie Pharmaceuticals, Inc; Equity Owner – GlobeChek; Advisor – AI Optics, Zeiss; Grant Support – New World Medical Inc, Save Vision Foundation; Research support and consultant – Topcon Medical Systems Inc; Consultant – Verily.. M.C.: Grant support – NIH, NSF, Genentech; Consultant – Novartis; Equity owner – InTeleretina, LLC.. F.A.M.: Consultant – Aerie Pharmaceuticals, Annexon, Biogen, Galimedix, IDx, Stealth Biotherapeutics; Consultant/Financial support – Allergan, Carl ZeissMeditec, Reichert, Novartis; Financial support – Google Inc, Heidelberg Engineering, Novartis; Patent – nGoggle Inc.. L.Z.: Grant support – National Eye Institute; Equipment and research support – Carl Zeiss Meditec Inc, Heidelberg Engineering GmbH, Optovue Inc, Topcon Medical Systems Inc, Patent Zeiss Meditec.. Financial Support: Funding from the National Institutes of Health (Bethesda, MD) R01-EY013178 and an unrestricted grant from Research to Prevent Blindness (New York, NY) to the Department of Ophthalmology, NYU Langone Health, NYU Grossman School of Medicine (New York, NY).. Obtained funding: N/A; Study was performed as part of the authors' regular employment duties. No additional funding was provided. Funding Information: M.C.: Grant support – NIH, NSF, Genentech; Consultant – Novartis; Equity owner – InTeleretina, LLC. Publisher Copyright: {\textcopyright} 2022 American Academy of Ophthalmology",

year = "2022",

month = may,

day = "1",

doi = "10.1016/j.ogla.2021.12.003",

language = "English",

volume = "5",

pages = "e3--e13",

journal = "Ophthalmology. Glaucoma",

issn = "2589-4234",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - A Case for the Use of Artificial Intelligence in Glaucoma Assessment

AU - Collaborative Community on Ophthalmic Imaging Executive Committee and Glaucoma Workgroup

AU - Schuman, Joel S.

AU - De Los Angeles Ramos Cadena, Maria

AU - McGee, Rebecca

AU - Al-Aswad, Lama A.

AU - Medeiros, Felipe A.

AU - Abramoff, Michael

AU - Blumenkranz, Mark

AU - Chew, Emily

AU - Chiang, Michael

AU - Eydelman, Malvina

AU - Myung, David

AU - Shields, Carol

AU - Antony, Bhavna J.

AU - Aung, Tin

AU - Boland, Michael

AU - Brunner, Tom

AU - Chang, Robert T.

AU - Chauhan, Balwantray

AU - Cherwek, D. Hunter

AU - Garway-Heath, David

AU - Graves, Adrienne

AU - Goldberg, Jeffrey L.

AU - He, Minguang

AU - Hammel, Naama

AU - Hood, Donald

AU - Ishikawa, Hiroshi

AU - Leung, Chris

AU - Pasquale, Louis

AU - Quigley, Harry A.

AU - Roberts, Calvin W.

AU - Robin, Alan L.

AU - Sturman, Elena

AU - Susanna, Remo

AU - Vianna, Jayme

AU - Zangwill, Linda

N1 - Funding Information: L.A.A.: Consultant/Advisor – Aerie Pharmaceuticals, Inc; Equity Owner – GlobeChek; Advisor – AI Optics, Zeiss; Grant Support – New World Medical Inc, Save Vision Foundation; Research support and consultant – Topcon Medical Systems Inc; Consultant – Verily. Funding Information: The author(s) have made the following disclosure(s): J.S.S.: Consultant/Advisor, Equity Owner – Aerie Pharmaceuticals Inc, Ocular Therapeutix Inc, Opticient; Grant Support – BrightFocus Foundation, National Eye Institute; Consultant/Advisor – Boehringer Ingelheim, Perfuse Inc, Regeneron Inc, Slack Incorporated; Patents/Royalty/Consultant/Advisor – Carl Zeiss Meditec; Intellectual Property – Massachusetts Eye and Ear Infirmary and Massachusetts Institute of Technology, New York University, Tufts University, University of Pittsburgh; Equity Owner, Patents/Royalty – Ocugenix.. L.A.A.: Consultant/Advisor – Aerie Pharmaceuticals, Inc; Equity Owner – GlobeChek; Advisor – AI Optics, Zeiss; Grant Support – New World Medical Inc, Save Vision Foundation; Research support and consultant – Topcon Medical Systems Inc; Consultant – Verily.. M.C.: Grant support – NIH, NSF, Genentech; Consultant – Novartis; Equity owner – InTeleretina, LLC.. F.A.M.: Consultant – Aerie Pharmaceuticals, Annexon, Biogen, Galimedix, IDx, Stealth Biotherapeutics; Consultant/Financial support – Allergan, Carl ZeissMeditec, Reichert, Novartis; Financial support – Google Inc, Heidelberg Engineering, Novartis; Patent – nGoggle Inc.. L.Z.: Grant support – National Eye Institute; Equipment and research support – Carl Zeiss Meditec Inc, Heidelberg Engineering GmbH, Optovue Inc, Topcon Medical Systems Inc, Patent Zeiss Meditec.. Financial Support: Funding from the National Institutes of Health (Bethesda, MD) R01-EY013178 and an unrestricted grant from Research to Prevent Blindness (New York, NY) to the Department of Ophthalmology, NYU Langone Health, NYU Grossman School of Medicine (New York, NY).. Obtained funding: N/A; Study was performed as part of the authors' regular employment duties. No additional funding was provided. Funding Information: M.C.: Grant support – NIH, NSF, Genentech; Consultant – Novartis; Equity owner – InTeleretina, LLC. Publisher Copyright: © 2022 American Academy of Ophthalmology

PY - 2022/5/1

Y1 - 2022/5/1

N2 - We hypothesize that artificial intelligence (AI) applied to relevant clinical testing in glaucoma has the potential to enhance the ability to detect glaucoma. This premise was discussed at the recent Collaborative Community on Ophthalmic Imaging meeting, “The Future of Artificial Intelligence–Enabled Ophthalmic Image Interpretation: Accelerating Innovation and Implementation Pathways,” held virtually September 3–4, 2020. The Collaborative Community on Ophthalmic Imaging (CCOI) is an independent self-governing consortium of stakeholders with broad international representation from academic institutions, government agencies, and the private sector whose mission is to act as a forum for the purpose of helping speed innovation in healthcare technology. It was 1 of the first 2 such organizations officially designated by the Food and Drug Administration in September 2019 in response to their announcement of the collaborative community program as a strategic priority for 2018–2020. Further information on the CCOI can be found online at their website (https://www.cc-oi.org/about). Artificial intelligence for glaucoma diagnosis would have high utility globally, because access to care is limited in many parts of the world and half of all people with glaucoma are unaware of their illness. The application of AI technology to glaucoma diagnosis has the potential to broadly increase access to care worldwide, in essence flattening the Earth by providing expert-level evaluation to individuals even in the most remote regions of the planet.

AB - We hypothesize that artificial intelligence (AI) applied to relevant clinical testing in glaucoma has the potential to enhance the ability to detect glaucoma. This premise was discussed at the recent Collaborative Community on Ophthalmic Imaging meeting, “The Future of Artificial Intelligence–Enabled Ophthalmic Image Interpretation: Accelerating Innovation and Implementation Pathways,” held virtually September 3–4, 2020. The Collaborative Community on Ophthalmic Imaging (CCOI) is an independent self-governing consortium of stakeholders with broad international representation from academic institutions, government agencies, and the private sector whose mission is to act as a forum for the purpose of helping speed innovation in healthcare technology. It was 1 of the first 2 such organizations officially designated by the Food and Drug Administration in September 2019 in response to their announcement of the collaborative community program as a strategic priority for 2018–2020. Further information on the CCOI can be found online at their website (https://www.cc-oi.org/about). Artificial intelligence for glaucoma diagnosis would have high utility globally, because access to care is limited in many parts of the world and half of all people with glaucoma are unaware of their illness. The application of AI technology to glaucoma diagnosis has the potential to broadly increase access to care worldwide, in essence flattening the Earth by providing expert-level evaluation to individuals even in the most remote regions of the planet.

UR - http://www.scopus.com/inward/record.url?scp=85124939357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124939357&partnerID=8YFLogxK

U2 - 10.1016/j.ogla.2021.12.003

DO - 10.1016/j.ogla.2021.12.003

M3 - Article

C2 - 34954220

AN - SCOPUS:85124939357

SN - 2589-4234

VL - 5

SP - e3-e13

JO - Ophthalmology. Glaucoma

JF - Ophthalmology. Glaucoma

IS - 3

ER -

A Case for the Use of Artificial Intelligence in Glaucoma Assessment

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Fingerprint

Cite this